Arcutis to Present at Upcoming Investor Conferences
September 09 2021 - 4:10PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations in immuno-dermatology to address the urgent needs of
patients living with immune-mediated dermatological diseases and
conditions, today announced that Arcutis management will
participate in two upcoming investor conferences in September.
Details for the company’s participation are as follows:
- Morgan Stanley 19th
Annual Global Healthcare
ConferenceFireside Chat
Date: Wednesday, September 15, 2021Fireside
Chat Time: 10:15 a.m. EDT
- Cantor Virtual Global Healthcare
ConferenceFireside Chat
Date: Monday, September 27, 2021Fireside Chat
Time: 11:20 a.m. EDT
Webcasts for these conferences may be accessed at the “Events
& Presentations” section of the Company’s Investor website
at https://investors.arcutis.com/events-and-presentations.
Additionally, a replay of the webcasts will be available on the
Arcutis website following the conferences.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of patients
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis harnesses our unique dermatology
development platform coupled with our dermatology expertise to
build differentiated therapies against biologically validated
targets. Arcutis’ dermatology development platform
includes a robust pipeline with seven clinical programs for a range
of inflammatory dermatological conditions, with our first NDA
submission late in the third quarter or early in the fourth quarter
of 2021 and three more Phase 3 clinical data readouts anticipated
by the end of 2022. The company’s lead product candidate, topical
roflumilast, has the potential to advance the standard of care for
plaque psoriasis, atopic dermatitis, scalp psoriasis, and
seborrheic dermatitis. For more information,
visit www.arcutis.com or follow Arcutis
on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for roflumilast to revolutionize
the standard of care in plaque psoriasis and other inflammatory
dermatological conditions. These statements involve substantial
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance, or
achievements to be materially different from the information
expressed or implied by these forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Risks and uncertainties that may cause our actual results to differ
include risks inherent in the clinical development process and
regulatory approval process, the timing of regulatory filings, and
our ability to defend our intellectual property. For a further
description of the risks and uncertainties applicable to our
business, see the "Risk Factors" section of our Form 10-K filed
with U.S. Securities and Exchange Commission (SEC) on February 16,
2021, as well as any subsequent filings with the SEC. We undertake
no obligation to revise or update information herein to reflect
events or circumstances in the future, even if new information
becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
(805) 418-5006
asheldon@arcutis.com
Investors
Eric McIntyre, Head of Investor Relations
(805) 418-5006
emcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024